# PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients

> **NCT00174356** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 39 (—)

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **DRUG:** CI 1033
- **DRUG:** PACLITAXEL
- **DRUG:** CARBOPLATIN

## Key facts

- **NCT ID:** NCT00174356
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 39 (—)
- **Last updated:** 2006-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174356, "PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00174356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*